Because pituitary GH release is inhibited by GIH and hypothalamic secretion of this peptide seems to be mainly dependent on 8-adrenergic regulation,we have investigated if BAB could modify the pattern of GH response to GRF-29 in 5SN (3V,2F;7.8-9.6 y) and lF; .Blood samples for GH where collected from -15'to+ 60'according the following tests:' A)Propranolol(1 mg/kg,as iv bolus at -6O');B)GRF(l mcg/kg,as iv bo-
lus at O');C)Propranolol(as in A)+GRF(as in B 5 children (8.24+/-3.63 years) with growth retardation (3.4 +/-0.9 DS)bone age retardation (3.13+/-2.40 years) and insufficient growth velocity (3.9+/-0.6 cmlyear) related with complete (n=2) or partial (n=3) GH deficiency were treated with a daily dose of 300 mcg GRF administred subcutaneously (SC)every other week for a 6 months period. GH response to SC GRF administration, GH and GRF antibodies and somatomedins were studied on repeated blood samples performed on day I and day 8 of the first week of treatment as well as at the end of the 6 months therapy. Growth velocity increased to 6.16+/-1.17 cmlyear. 3 of the 5 patients have accelerated growth mainly for the first 3 months. Linear growth was increased in complete (+2.5 and 4.3 cmlyear) more than in partial (+0.4, +0.8 and +3.3 cm/year) GR deficient children. The area under the GH curve after GRF administration was 1050.7+/-767.7 on day 1, 472.1+/-103.2 on day 8 and 631.9 +/-148.1 ng/ml x min. after 6 months therapy. No major change in other hormonal evaluations was noted. These results confirm that GRF can stimulate linear growth in some GH deficient children and lead to discuss the role of limiting factors in its long term effects such as desensitization, antibodies or somatostatin. We have treated 1 1 prepubertal children (7M;4F) with height velocity and partial GH deficiency in response to two idiopathic GH deficiency due to pituitary hypoplasia using pharmacological tests (maximum peak 11 ng/ml) GRF for GHRH 1-40. This was administered subcutaneously for 4 ~ulses 6 months (10 mcg/kg/day) as a subcutaneous injection (8 p.m.).
at 3 hourly intervals at night in a dose of 1-2flg/kg/pulse.
24-hours GH secretion was studied before and after 3 months of Blood samples for GH concentrations were taken at 20 minute treatment : SmC dosage and a IV GRF test ( 2 mcg/kg) was done intervals for 24 hours before treatment and throughout the before and after 6 months of treatment. Lower leg length was stuStudy at night' died every 3 weeks by knemometry and statural growth at 3 months Pulsatile GH secretion was induced in 10 children from the intervals. first night of treatment and the response augmented with time.
Height velocity increased In cases from 2.5 + 0.5 to 4.4 + Growth velocity in 8 of 1 1 children increased from 3.3cm/yr 1.1 cm for the 6 months perlod and showed no change in 2 cases.
(range 1.7 to 4.9) before treatment to 6.9cm/~r (range 5-8.5) Knemometric growth rate is subject to wide variations and is dlf-0 " GHRH. 2 children had no change in height velocity and one ficult to take into account. There was no sign of desensitization: had a progressive diminution of GH secretion and a fall in growth 24-hour secretion (mx peak and I.C.) was higher after 3 months velocity.
treatment (m = 16.2 2 7.5 ng/ml and 3.7 + 1.2 ng/ml/min before, GHRH (lug/kg) was also administered intravenously to all 29 + 17.9 ng/ml and 4.5 + ng/ml/min afterwards), as was the GH children before treatment and at 3 monthly intervals. Although peak in the IV GRF test after 6 months treatment ( m = 36.1 ng/ml a response was seen on all occasions, the responses ~redicted before, 47.8 ng/ml afterwards). SmC level was hlgher on average neither the GH the growth after 6 months treatment (1.9 + 1 U/ml and 0.8 + 0.5 U/ml before On long term s.c. treatment. treatment). The analysis of the various parameters (GH secretion, Pulsatile administration of GHRH 1-40 was effective in SmC) provided no elements to account for the lack of therapeutic inducing GH secretion and promoting growth acceleration in the response in the 2 cases. These results suggest that GRF treatment with GH may be considered as a therapeutic alternative in GH deficienc~es. 
INSULIN-LIKE GROWTH FACTOR I / SOMATOMEDIN C (IGF I/
Starting from Cohn fraction IV of human plasma we earlier des7he biocklenical and gm&h respnses t . CHW(1-29)W therapy were studied cribed a multiple step procedure which resulted in ug amount of in 1 8 preplbertal BCdeficient children (14 idiopathic, 3 cranial irradiation, IGF I/SmC of relative high purity (200 pU/pg)+.
1 septooptic dysplasia; 16 male, 2 fmale, rean age 9.5 years, rmge 6.e -
In the meanwhile we have further modified this method: 20 grs. of 1 4 . ' 5 ' -) .
deficiew -defined as a GH to stin*atim Of less acetone dried Cohn fraction IV are suspended in 1% NaCl/fornic ' -k e n Children had treahnent which was at Ieast acid, pH 3.0. After precipitation of the IGF I containing pro-3 mnths before the trial. W U f was given as M c e daily sc injections in teins in the supernatant by addition of 5 M NaCl the precipitate irdiviw dases of 250 pg (children less than 20 kg bw), and 500 pg (greater is resuspended in 2 N acetic acid (AA) /ethanol (1:4). Denatured thm 20 IW). --pm to -t-~cent was a.8
proteins are discarded by centrifugation, and after evaporation (mnn + SE) and after 3 mnths 27.4 + 4.2 nU/l; indicating m desensitisation the supernatant is chromatographed on Sephadex G 50 in 1 N AA.
effect. 'Ihirthe l8 an in hekht mnths IGF I containing fractions (approx. 12 pg IGF I , purity of approx.
therapy, in 6 this was greater than 2 on/year and in 3 greater than 5 an/year. 90%) are purified by lmmobilineR isoelectric focusing (IEF) (pH mree children s M a m t e r height velocity on CWW than on m. Ei@t 8-10). The IGF I band, focusing at pH 8.3 finally is purified children have mpleted 6 m t h s URrapy and 3 b e shmn an i n c m n t i n using a HPLC reversed phase C-18 column in a 25-65% acetonitrile he@t velEity Of 0.47 2.52 and 3.1 on'year. 
